NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A nebulous matter.

[1]  M. Karsdal,et al.  Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. , 2019, Journal of hepatology.

[2]  K. Lindor,et al.  Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis , 2018, Hepatology.

[3]  K. Lindor,et al.  Complications, symptoms, quality of life and pregnancy in cholestatic liver disease , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[4]  J. Tabibian,et al.  Primary sclerosing cholangitis: A review and update. , 2017, Liver research.

[5]  T. Karlsen,et al.  Enhanced liver fibrosis test predicts transplant‐free survival in primary sclerosing cholangitis, a multi‐centre study , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[6]  F. Lund-Johansen,et al.  Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. , 2017, Journal of hepatology.

[7]  Hong Yang,et al.  Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis , 2017, Nature Communications.

[8]  J. Tabibian,et al.  The evolution of natural history of primary sclerosing cholangitis , 2016, Current opinion in gastroenterology.

[9]  C. Ponsioen,et al.  Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge , 2016, Hepatology International.

[10]  G. Gores,et al.  Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process , 2016, Hepatology.

[11]  K. Lindor,et al.   Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis. , 2016, Annals of hepatology.

[12]  R. M. Learned,et al.  Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2‐deficient mice , 2015, Hepatology.

[13]  K. Lindor,et al.  Ursodeoxycholic acid in primary sclerosing cholangitis: If withdrawal is bad, then administration is good (right?) , 2014, Hepatology.

[14]  N. LaRusso,et al.  AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Cholangiocyte Senescence by Way of N-Ras Activation Is a Characteristic of Primary Sclerosing Cholangitis , 2014 .

[15]  J. Talwalkar,et al.  Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis. , 2014, Annals of hepatology.

[16]  N. LaRusso,et al.  The dynamic biliary epithelia: molecules, pathways, and disease. , 2013, Journal of hepatology.

[17]  K. Lindor,et al.  Challenges of Cholangiocarcinoma Detection in Patients with Primary Sclerosing Cholangitis , 2012, Journal of analytical oncology.

[18]  C. Benz,et al.  [Primary sclerosing cholangitis]. , 2000, Der Internist.

[19]  E. AriasVallejo.  Primary sclerosing cholangitis , 1988 .